Protalix BioTherapeutics, Inc.
AMEX:PLXBiotechnology
+$0.09 today
- Market cap
- $254.64M
- Beta
- 0.01
- P/E (TTM)
- 11.0
- EPS (TTM)
- $0.19
Volume 0.96M
Average 0.81M
PLX Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Protalix BioTherapeutics, Inc.AMEX: PLX
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin widens to 87.8%
Gross margin was 87.8% in Q1 FY2026, up 68.7 pp from a year earlier. On a trailing-twelve-month basis it was 70.0%, up 20.0 pp year over year. Over 3 fiscal years it narrowed by 11.0 pp.
Context
- Gross margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 47.8%
- Year-over-year change
- -6.6pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.8% | -6.6pp |
| FY2024 | 2024-12-31 | 54.5% | -10.5pp |
| FY2023 | 2023-12-31 | 64.9% | +6.0pp |
| FY2022 | 2022-12-31 | 58.9% | +1.5pp |
| FY2021 | 2021-12-31 | 57.4% | — |
Gross Margin vs competitors
How PLX compares with its peers on the latest reported figures
- PLX's LTM Mar 2026 gross margin of 70.0% is the lowest of the 3 companies compared; the peer median is 85.4%.
- Its year-over-year change of +20.0 pp is the highest of 3, against a peer median of -1.6 pp.
- Over three fiscal years its change of -11.0 pp compares with a peer median of -6.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 87.3% | -1.7 pp | -3.6 pp | |
| LTM Mar 2026 | 83.6% | -1.6 pp | -8.4 pp | |
| LTM Mar 2026 | 70.0% | +20.0 pp | -11.0 pp | |
PLYXPolaryx Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding PLX) | 85.4% | -1.6 pp | -6.0 pp | |
Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 38.35M | 47.64M | 65.49M | 53.4M | 52.74M |
| Cost of Revenue | 16.35M | 19.59M | 22.98M | 24.32M | 27.51M |
| Gross Profit | 22M | 28.05M | 42.51M | 29.08M | 25.24M |
| Gross Margin | 57.4% | 58.9% | 64.9% | 54.5% | 47.8% |
| Research & Development | 29.73M | 29.35M | 17.09M | 12.97M | 19.05M |
| Selling, General & Admin | 12.73M | 11.71M | 14.96M | 12.19M | 11.68M |
| Operating Expenses | 42.46M | 41.06M | 32.05M | 25.16M | 30.74M |
| Depreciation & Amortization | 1.12M | 1.09M | 1.19M | 1.3M | 1.47M |
| EBITDA | (18.94M) | (10.78M) | 12.94M | 6.52M | (2.95M) |
| EBITDA Margin | -49.4% | -22.6% | 19.8% | 12.2% | -5.6% |
| Operating Income | (20.46M) | (13.01M) | 10.46M | 3.92M | (5.5M) |
| Operating Margin | -53.4% | -27.3% | 16.0% | 7.3% | -10.4% |
| Interest Income | 401K | 1.15M | 1.29M | 1.3M | 1.08M |
| Interest Expense | 7.52M | 2.53M | 3.18M | 1.06M | 1.19M |
| Other Income / Expenses | (7.12M) | (1.38M) | (1.89M) | 237K | (108K) |
| Income Before Tax | (27.58M) | (14.4M) | 8.57M | 4.15M | (5.61M) |
| Pre-Tax Margin | -71.9% | -30.2% | 13.1% | 7.8% | -10.6% |
| Income Tax Expense | 0 | 530K | 254K | 1.22M | 996K |
| Net Income | (27.58M) | (14.93M) | 8.31M | 2.93M | (6.6M) |
| Net Margin | -71.9% | -31.3% | 12.7% | 5.5% | -12.5% |
| EPS (Basic) | (0.62) | (0.31) | 0.12 | 0.04 | (0.08) |
| EPS (Diluted) | (0.62) | (0.31) | 0.10 | 0.04 | (0.08) |
| Weighted Avg Shares | 44.14M | 48.47M | 67.51M | 72.53M | 78.55M |
| Weighted Avg Shares (Diluted) | 44.14M | 48.47M | 82.42M | 81.06M | 78.55M |
Protalix BioTherapeutics, Inc.
AMEX:PLX
Intrinsic Alpha fair value
Locked
Current Price
$3.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.